|This Slide: #39 of 100|
Slide #39. NeoStem — California Stem Cell, Inc.
California Stem Cell, Inc.
NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that it has entered into a definitive agreement to acquire California Stem Cell, Inc. ("CSC"), an Irvine, California based stem cell biotechnology company. As a result of this acquisition, NeoStem plans to initiate a pivotal Phase 3 trial of Melapuldencel-T, an autologous melanoma initiating (stem) cell immune based therapy intended to eliminate the tumor cells capable of causing disease recurrence.
NeoStem is engaged in the development of proprietary cell therapy products, and operating a contract development and manufacturing organization providing services in the regenerative medicine industry. Co. is developing therapies to address ischemia through its CD34 Cell Program. AMR-001 is Co.'s product candidate in this program and is being developed to treat damaged heart muscle following an acute myocardial infarction (heart attack). Another platform technology Co. is developing uses T Regulatory Cells to treat diseases caused by imbalances in the immune system. In addition, pre-clinical assets include Co.'s VSEL™ (Very Small Embryonic Like) Technology regenerative medicine platform.
Open the NBS Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 82% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite